News From the 2020 Multidisciplinary Head and Neck Cancers Symposium

This week, we'll hear from two researchers on findings presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. We'll also review the FDA's approval of isatuximab-irfc as part of a triplet regimen for patients with relapsed or refractory multiple myeloma.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Isatuximab-irfc–Based Triplet Regimen for Patients With Relapsed or Refractory Multiple Myeloma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll hear from two researchers on findings presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. We'll also review the FDA's approval of isatuximab-irfc as part of a triplet regimen for patients with relapsed or refractory multiple myeloma.

This week, we'll hear from two researchers on findings presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. We'll also review the FDA's approval of isatuximab-irfc as part of a triplet regimen for patients with relapsed or refractory multiple myeloma.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Isatuximab-irfc–Based Triplet Regimen for Patients With Relapsed or Refractory Multiple Myeloma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

This week, we'll hear from two researchers on findings presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. We'll also review the FDA's approval of isatuximab-irfc as part of a triplet regimen for patients with relapsed or refractory multiple myeloma.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Isatuximab-irfc–Based Triplet Regimen for Patients With Relapsed or Refractory Multiple Myeloma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Isatuximab-irfc–Based Triplet Regimen for Patients With Relapsed or Refractory Multiple Myeloma